Quantbot Technologies LP Grows Stock Position in AMNEAL PHARMACEUTICALS, INC. $AMRX

Key Points

• Quantbot Technologies LP increased its stake in Amneal Pharmaceuticals by 124.9%, owning 268,805 shares valued at approximately $2.25 million.
• Amneal Pharmaceuticals recently reported earnings of $0.23 per share, surpassing analyst expectations by $0.06, and set its FY 2025 guidance for earnings at 0.700-0.750 EPS.
• Goldman Sachs initiated coverage with a "buy" rating and a price target of $12.00, while the company's consensus target price is currently set at $11.60.

Quantbot Technologies LP raised its stake in shares of AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) by 124.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 268,805 shares of the company's stock after purchasing an additional 149,272 shares during the period. Quantbot Technologies LP owned 0.09% of AMNEAL PHARMACEUTICALS worth $2,253,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nuveen LLC acquired a new stake in shares of AMNEAL PHARMACEUTICALS in the first quarter valued at $19,581,000. Nantahala Capital Management LLC increased its position in AMNEAL PHARMACEUTICALS by 37.3% in the fourth quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company's stock worth $29,031,000 after purchasing an additional 995,586 shares during the period. Vanguard Group Inc. increased its position in AMNEAL PHARMACEUTICALS by 6.2% in the first quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company's stock worth $132,092,000 after purchasing an additional 920,758 shares during the period. Bank of America Corp DE boosted its holdings in AMNEAL PHARMACEUTICALS by 218.8% during the fourth quarter. Bank of America Corp DE now owns 556,881 shares of the company's stock worth $4,410,000 after buying an additional 382,222 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in AMNEAL PHARMACEUTICALS during the fourth quarter worth about $2,946,000. Institutional investors and hedge funds own 31.82% of the company's stock.

Insiders Place Their Bets

In related news, EVP Jason B. Daly sold 22,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total transaction of $199,100.00. Following the completion of the sale, the executive vice president owned 10,606 shares of the company's stock, valued at $95,984.30. This trade represents a 67.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Andrew S. Boyer sold 279,244 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total value of $2,619,308.72. Following the completion of the transaction, the executive vice president owned 152,426 shares in the company, valued at approximately $1,429,755.88. The trade was a 64.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 577,206 shares of company stock valued at $5,405,265 in the last 90 days. Corporate insiders own 17.45% of the company's stock.

AMNEAL PHARMACEUTICALS Stock Up 0.4%

Shares of NASDAQ:AMRX traded up $0.04 during trading on Tuesday, reaching $9.32. 142,073 shares of the company traded hands, compared to its average volume of 1,675,040. The company's 50 day moving average is $8.40 and its two-hundred day moving average is $8.02. The firm has a market capitalization of $2.93 billion, a PE ratio of 931.23 and a beta of 1.11. AMNEAL PHARMACEUTICALS, INC. has a 52 week low of $6.68 and a 52 week high of $9.79.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a negative return on equity of 189.49% and a net margin of 0.12%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, research analysts anticipate that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on AMRX. Wall Street Zen cut AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. The Goldman Sachs Group started coverage on AMNEAL PHARMACEUTICALS in a research report on Friday, June 6th. They set a "buy" rating and a $12.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $11.60.

About AMNEAL PHARMACEUTICALS

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.